AIDS Research and Treatment oracle inequalities and examples,” Tech. Rep. number 130, Division of Biostatistics, University of California, Berkeley, Calif, USA, http://www.bepress.com/ucbbiostat/paper130/, 2003. [19] M. J. van der Laan and R. Sherri, Targeted Learning: Causal Inference for Observational and Experimental Data, Springer, 2011. [20] S. E. Sinisi, E. C. Polley, M. L. Petersen, S. Y. Rhee, and M. J. van der Laan, “Super learning: an application to the prediction of HIV-1 drug resistance,” Statistical Applications in Genetics and Molecular Biology, vol. 6, no. 1, article 7, pp. 1–24, 2007. [21] M. J. van der Laan, E. C. Polley, and A. E. Hubbard, Super Learner, Working Paper Series, U.C. Berkeley Division of Biostatistics, 2007. [22] E. C. Polley and M. J. van der Laan, Super Learner in Prediction, Working Paper 266, U.C. Berkeley Division of Biostatistics, 2010. [23] L. Rosasco, E. de Vito, A. Caponnetto, M. Piana, and A. Verri, “Are loss functions all the same?” Neural Computation, vol. 16, no. 5, pp. 1063–1076, 2004. [24] J. M. Molina, A. G. Marcelin, J. Pavie et al., “Didanosine in HIV-1-infected patients experiencing failure of antiretroviral therapy: a randomized placebo-controlled trial,” Journal of Infectious Diseases, vol. 191, no. 6, pp. 840–847, 2005. [25] I. C. Marschner, R. A. Betensky, V. DeGruttola, S. M. Hammer, and D. R. Kuritzkes, “Clinical trials using HIV-1 RNA-based primary endpoints: statistical analysis and potential biases,” Journal of Acquired Immune Deﬁciency Syndromes and Human Retrovirology, vol. 20, no. 3, pp. 220–227, 1999. [26] P. Flandre, C. Durier, D. Descamps, O. Launay, and V. Joly, “On the use of magnitude of reduction in HIV-1 RNA in clinical trials: statistical analysis and potential biases,” Journal of Acquired Immune Deﬁciency Syndromes, vol. 30, no. 1, pp. 59–64, 2002. [27] P. Flandre, A. Alcais, D. Descamps, L. Morand-Joubert, and V. Joly, “Estimating and comparing reduction in HIV-1 RNA in clinical trials using methods for interval censored data,” Journal of Acquired Immune Deﬁciency Syndromes, vol. 35, no. 3, pp. 286–292, 2004. [28] S. Y. Rhee, J. Taylor, G. Wadhera, A. Ben-Hur, D. L. Brutlag, and R. W. Shafer, “Genotypic predictors of human immun- odeﬁciency virus type 1 drug resistance,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 46, pp. 17355–17360, 2006. [29] M. Rabinowitz, L. Myers, M. Banjevic et al., “Accurate predic- tion of HIV-1 drug response from the reverse transcriptase and protease amino acid sequences using sparse models created by convex optimization,” Bioinformatics, vol. 22, no. 5, pp. 541–549, 2006. [30] I. Ruczinski, C. Kooperberg, and M. Leblanc, “Logic regres- sion,” Journal of Computational and Graphical Statistics, vol. 12, no. 3, pp. 475–511, 2003. [31] S. E. Sinisi and M. J. van der Laan, “Deletion/substitu- tion/addition algorithm in learning with applications in genomics,” Statistical Applications in Genetics and Molecular Biology, vol. 3, no. 1, article 18, 2004. [32] L. Breiman, J. Friedman, C. Stone, and R. A. Olshen, Class- iﬁcation and Regression Trees, Chapman and Hall/CRC, 1984. [33] L. Breiman, “Random forests,” Machine Learning, vol. 45, no. 1, pp. 5–32, 2001. [34] M. C. F. Prosperi, A. Altmann, M. Rosen-Zvi et al., “Investiga- tion of expert rule bases, logistic regression, and non- linear machine learning techniques for predicting response to antiretroviral treatment,” Antiviral Therapy, vol. 14, no. 3, pp. 433–442, 2009. 7 [35] A. G Marcelin, P. Flandre, J. Pavie et al., “New genotypic score comprising mutations impacting negatively and positively the virological response to didanosine in treatment-experienced patients from the randomized didanosine add on Jaguar study,” Antiviral Therapy, vol. 9, pp. U102–U102, 2004. [36] B. Masquelier, K. L. Assoumou, D. Descamps et al., “Clinically validated mutation scores for HIV-1 resistance to fosampre- navir/ritonavir,” Journal of Antimicrobial Chemotherapy, vol. 61, no. 6, pp. 1362–1368, 2008. [37] S. Vora, A. G. Marcelin, H. F. G u¨nthard et al., “Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients,” AIDS, vol. 20, no. 1, pp. 35–40, 2006. [38] P. Flandre, A. G. Marcelin, J. Pavie et al., “Comparison of tests and procedures to build clinically relevant genotypic scores: application to the Jaguar study,” Antiviral Therapy, vol. 10, no. 4, pp. 479–487, 2005. [39] A. G. DiRienzo, V. DeGruttola, B. Larder, and K. Hertogs, “Non-parametric methods to predict HIV drug susceptibility phenotype from genotype,” Statistics in Medicine, vol. 22, no. 17, pp. 2785–2798, 2003.